On Monday, Novo Nordisk announced that the results from its Phase 3 trial investigating semaglutide as a treatment for Alzheimer’s “did not confirm the superiority of semaglutide versus placebo in the reduction of progression,” of the disease, according to the press release. Monday’s announcement had a silver lining. That is, the treatment did result in…
Shifting mindsets all around: clinical thinking about Alzheimer’s disease moves from symptoms treatment toward earlier intervention and prevention
Alzheimer’s disease remains one of the most complex and devastating neurodegenerative disorders, affecting over 55 million people globally. With projections estimating this number will rise to 139 million by 2050, the urgency to develop effective treatments has never been greater. Historically, AD drug development has been marked by setbacks and limited therapeutic success due to…